Lazard Capital Downgrades Abiomed (ABMD) to Hold
More News related to ABMD
- Abiomed Inc. (ABMD) Posts Q3 Loss of $0.12, Narrower than Estimated
- Abiomed (ABMD) Reports Smaller-Than-Expected Q3 Loss
- Trading Radar for 02/04: Bunge (BG), Spectra Energy (SE), MasterCard (MA), Con-Way (CNW), Hospira (HSP) Report
- Abiomed Third Fiscal Quarter 2010 Earnings and Conference Call Notification
- Abiomed Announces Partnership with Opsens to Utilize Sensor Technology for Impella
More News related to Downgrades
- S&P Lowers Pinnacle Entertainment (PNK) Outlook from Stable to Negative
- Mindspeed (MSPD) Moving Lower as Brigantine Downgrades to Hold
- Davenport Downgrades Electronic Arts (ERTS) to Sell; Lowers Q4, 2010-11 Estimates
- Stifel Nicolaus Downgrades Parkway Properties (PKY) to Sell
- Craig-Hallum Downgrades Terremark (TMRK) to Accumulate
Lazard Capital downgrades Abiomed (Nasdaq: ABMD) from Buy to Hold.
To see more analyst ratings on ABMD Click Here.
Abiomed Inc. is a provider of medical devices in circulatory support that offers a continuum of care in heart recovery to heart failure patients.
Related Categories
DowngradesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
